Abstract 4373591: PREVENT in the 75-and-older population and additional prognostic value of coronary artery calcium: the Atherosclerosis Risk in Communities (ARIC) study

Y Yejin Mok (Johns Hopkins University, Baltimore, Maryland, United States) Y Yasuyuki Honda (Johns Hopkins Bloomberg School, Baltimore, Maryland, United States) F Frances Wang (Beth Israel Deaconess Med Center, Diamond Bar, California, United States) C Candace Howard (University of Mississippi Medical C, Jackson, Mississippi, United States) A Aaron Folsom (UNIVERSITY OF MINNESOTA, Minneapolis, Minnesota, United States) J Josef Coresh M Matthew Budoff (The Lundquist Institute, Torrance, California, United States) M Michael Blaha (JOHNS HOPKINS HOSPITAL, Baltimore, Maryland, United States) K Kunihiro Matsushita (Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (K.M.).)

Abstract

Background: The American Heart Association recently released the Predicting Risk of cardiovascular disease EVENTs (PREVENT) equation for estimating cardiovascular disease (CVD) risk in primary prevention adults aged 30-79. However, its performance in older adults aged 80 years and older is uncertain. Also, the utility of coronary artery calcium (CAC) for CVD prediction improvement beyond PREVENT is unknown. Methods: We studied 1,912 ARIC older adult participants (mean age 80 [SD 4] years) with CAC data but without a history of coronary heart disease (CHD), stroke, and heart failure (HF) at Visit 7 (2018-2019). We first assessed c-statistics and calibration indices of the PREVENT in our older adult population. Then, we compared the predictability between PREVENT and CAC, with total CVD (atherosclerotic CVD [ASCVD, including CHD and stroke] and HF), and all-cause mortality as outcomes of interest, using Cox regression models. Results: Over a median follow-up of 3.7 (IQI 2.6-4.3) years, there were 144 CVD events (81 ASCVD and 75 HF) and 210 deaths. PREVENT demonstrated good calibration (calibration slope 0.74 for total CVD) and discrimination (c-statistic 0.621), and the results were similar in participants aged 80+ vs. those aged 75-79 years. CAC significantly improved prediction of total CVD (0.078 [95% CI 0.034, 0.122]), ASCVD (0.083 [0.026, 0.140]), and HF (0.069 [0.016, 0.123]) beyond PREVENT, but this was not the case for all-cause mortality (left panel of Figure). In contrast, PREVENT improved only the prediction of all-cause mortality beyond CAC (right panel of Figure). The results were largely similar between the age of 80+ vs. 75-79. Conclusions: PREVENT overall performed well even in older adults aged 80+ years. CAC further improved CVD risk prediction beyond and above PREVENT in the-75-and-older adults. Our findings suggest broad usefulness of PREVENT and further support the value of CAC for assessment of primary CVD risk in very older adults.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue Suppl_3
Published November 04, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (9)

Y

Yejin Mok

Johns Hopkins University, Baltimore, Maryland, United States

Y

Yasuyuki Honda

Johns Hopkins Bloomberg School, Baltimore, Maryland, United States

F

Frances Wang

Beth Israel Deaconess Med Center, Diamond Bar, California, United States

C

Candace Howard

University of Mississippi Medical C, Jackson, Mississippi, United States

A

Aaron Folsom

UNIVERSITY OF MINNESOTA, Minneapolis, Minnesota, United States

J

Josef Coresh

M

Matthew Budoff

The Lundquist Institute, Torrance, California, United States

M

Michael Blaha

JOHNS HOPKINS HOSPITAL, Baltimore, Maryland, United States

K

Kunihiro Matsushita

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (K.M.).